Could a targeted pill boost chemo for a tough blood cancer?
NCT ID NCT03709758
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding the targeted drug venetoclax to standard chemotherapy can safely treat adults newly diagnosed with acute myeloid leukemia (AML). About 50 participants will receive the combination to find the best dose and see how many achieve remission. The goal is to improve on current treatments without causing too many extra side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (a targeted drug that helps kill cancer cells) combined with standard chemotherapy drugs daunorubicin and cytarabine
What this could lead to
If successful, this could lead to a more effective initial treatment for acute myeloid leukemia, potentially improving remission rates.
What could go wrong
This is an early Phase 1 trial with only 50 participants, so safety and dosing are still being figured out. The added drug may increase side effects without guaranteeing better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of Chicago
Chicago, Illinois, 60637, United States